The breast cancer drug Faslodex does not offer value for money to the NHS and is no better than existing treatments, according to NICE.
The agency’s final draft guidance ruled that Faslodex, also known as fulvestrant, should not be given out on the NHS to postmenopausal women who have oestrogen-receptor-positive advanced breast cancer and who have already received another anti-oestrogen therapy (such as tamoxifen).
AstraZeneca claimed it could extend life when compared with two existing drugs, anastrozole and letrozole, said NICE.
But the agency found the manufacturer’s assertion to be “considerably uncertain” and said evidence showed no statistically significant differences in overall survival. It did find Faslodex could delay cancer growth better than anastrozole, but said there was no evidence it was better at this function than letrozole.
The decision, which is subject to an appeals procedure, does not affect women already on Faslodex. They will be able to continue taking it until otherwise advised by their doctors.